Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.39 |
| ▸ | OGFRL1 | Q5TC84 | 8/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5015627 | 0.88 | GAA (0.40) | OPRM1OPRK1OGFRL1OPRD1GAA | |
| SCHEMBL5013555 | 0.78 | SMN1; SMN2 (0.41) | CYP2C9CYP2C19SMN1; SMN2KDM4E | |
| SCHEMBL5014017 | 0.75 | HDAC1 (0.43) | OPRM1OPRK1OGFRL1OPRD1GAA | |
| SCHEMBL5012191 | 0.71 | HDAC1 (0.43) | OPRM1OPRK1OGFRL1OPRD1GAA | |
| SCHEMBL5014189 | 0.67 | GAA (0.44) | OPRM1OPRK1OGFRL1OPRD1GAA | |
| SCHEMBL4739120 | 0.66 | MAPT (0.49) | OPRM1OPRK1OGFRL1OPRD1GAA | |
| SCHEMBL4294427 | 0.65 | OGFRL1 (0.48) | OPRM1OPRK1OGFRL1OPRD1GAA | |
| SCHEMBL5015628 | 0.65 | SMN1; SMN2 (0.44) | ALOX15CYP2C9CYP2C19SMN1; SMN2KDM4E | |
| SCHEMBL27574019 | 0.65 | L3MBTL1 (0.69) | OPRM1OPRK1OGFRL1OPRD1GAA | |
| SCHEMBL14382666 | 0.65 | L3MBTL1 (0.70) | OPRM1OPRK1OGFRL1OPRD1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249146-A1 | Imidazole and Thioazole Derivatives as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-10-09 | — | — | US | claimed |
| US-20080255038-A1 | 3-[(R)-2-(N,N-dimethylamino)ethylthio-Sar]-4-(gamma-hydroxymethylleucine)cyclosporin, for example, and pharmaceutical compositions prepared from the same, in combination with one or more NS5B polymerase inhibitors; use in treatment of hepatitis C virus; avoids need to use interferon or ribavirin | SCYNEXIS, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080249146-A1 | Imidazole and Thioazole Derivatives as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-10-09 | — | — | US | disclosed |
| US-20080249146-A1 | Imidazole and Thioazole Derivatives as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-10-09 | — | — | US | disclosed |
| US-20080249146-A1 | Imidazole and Thioazole Derivatives as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255038-A1 | 3-[(R)-2-(N,N-dimethylamino)ethylthio-Sar]-4-(gamma-hydroxymethylleucine)cyclosporin, for example, and pharmaceutical compositions prepared from the same, in combination with one or more NS5B polymerase inhibitors; use in treatment of hepatitis C virus; avoids need to use interferon or ribavirin | NSUN2, TPMT, EIF5B | OPRM1 1771/4885OPRK1 2126/4885OGFRL1 2620/4885 |
| US-20080249146-A1 | Imidazole and Thioazole Derivatives as Antiviral Agents | IRF3, HAVCR2, ZC3HAV1 | OPRM1 3014/4885OPRK1 2083/4885OGFRL1 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.